Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppression

International Journal of Oncology

Volumn 31, Issue 4, 2007, Pages 705-711

  Tang, Yan ^a   Zhao, Daniel Y ^a   Elliott, Steven ^a   Zhao, Weiqiang ^a   Curiel, Tyler J ^a   Beckman, Barbara S ^a   Burow, Matthew E ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

AKT; Apoptosis; Breast cancer; Epigallocatechin 3 gallate; Green tea; Survivin

Indexed keywords

ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; CATECHIN; DRUG DERIVATIVE; EPIGALLOCATECHIN GALLATE; LUCIFERASE; MICROTUBULE ASSOCIATED PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEINASE INHIBITOR; TUMOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST TUMOR; CLONOGENIC ASSAY; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; PATHOLOGY; PROMOTER REGION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTICARCINOGENIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CATECHIN; CELL LINE, TUMOR; COLONY-FORMING UNITS ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUCIFERASES; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PROMOTER REGIONS (GENETICS); PROTEASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 35848933017     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.4.705     Document Type: Article

References (56)

1. Imai K, Suga K and Nakachi K: Cancer-preventive effects of drinking green tea among a Japanese population. Prev Med 26: 769-775, 1997.
2. Kazi A, Smith DM, Daniel K, Zhong S, Gupta P, Bosley ME and Dou QP: Potential molecular targets of tea polyphenols in human tumor cells: significance in cancer prevention. In Vivo 16: 397-403, 2002.
3. Chen A and Zhang L: The antioxidant epigallocatechin-3-gallate inhibits rat hepatic stellate cells proliferation in vitro by blocking the tyrosine phosphorylation and reducing the gene expression of platelet-derived growth factor-β receptor. J Biol Chem 278: 23381-23389, 2003.
4. Gupta S, Hastak K, Ahmad N, Lewin JS and Mukhtar H: Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 98: 10350-10355, 2001. (Pubitemid 32803023)
5. Balentine DA, Wiseman SA and Bouwens LCM: The chemistry of tea flavonoids. Crit Rev Food Sci Nutr 37: 693-704, 1997.
6. Wiseman SA, Balentine DA and Frei B: Antioxidants in tea. Crit Rev Food Sci Nutr 37: 705-718, 1997.
7. Yang CS, Chen L, Lee M-J, Balentine D, Kuo MC and Schantz SP: Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol Biomarkers Prev 7: 351-354, 1998. (Pubitemid 28354149)
8. Nakagawa K, Okuda S and Miyazawa T: Dose-dependent incorporation of tea catechins, (-)-epigallocatechin-3-gallate and (-)-epigallocatechin, into human plasma. Biosci Biotechnol Biochem 61: 1981-1985, 1997.
9. Linden KG, Carpenter PM, McLaren CE, Barr RJ, Hite P, Sun JD, Li KT, Viner JL and Meyskens FL: Chemoprevention of non-melanoma skin cancer: experience with a polyphenol from green tea. Recent Results Cancer Res 163: 165-171, 2003.
10. Adhami VM, Ahmad N and Mukhtar H: Molecular targets for green tea in prostate cancer prevention. J Nutr 133: S2417-S2424, 2003. (Pubitemid 36828848)
11. Zhang H, Spitz MR, Tomlinson GE, Schabath MB, Minna JD and Wu X: Modification of lung cancer susceptibility by green tea extract as measured by the comet assay. Cancer Detect Prev 26: 411-418, 2002. (Pubitemid 36035370)
12. Guyton KZ and Kensler TW: Prevention of liver cancer. Curr Oncol Rep 4: 464-470, 2002.
13. Kemberling JK, Hampton JA, Keck RW, Gomez MA and Selman SH: Inhibition of bladder tumor growth by the green tea derivative epigallocatechin-3-gallate. J Urol 170: 773-776, 2003.
14. Sato D and Matsushima M: Preventive effects of urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine in rat by green tea leaves. Int J Urol 10: 160-166, 2003.
15. Hoshiyama Y, Kawaguchi T, Miura Y, Mizoue T, Tokui N, Yatsuya H, Sakata K, Kondo T, Kikuchi S, Toyoshima H, Hayakawa N, Tamakoshi A, Ohno Y and Yoshimura T: Japan Collaborative Cohort Study Group: a prospective study of stomach cancer death in relation to green tea consumption in Japan. Br J Cancer 87: 309-313, 2002.
16. Jung YD, Kim MS, Shin BA, Chay KO, Ahn BW, Liu W, Bucana CD, Gallick GE and Ellis LM: EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. Br J Cancer 84: 844-850, 2001.
17. Isemura M, Saeki K, Kimura T, Hayakawa S, Minami T and Sazuka M: Tea catechins and related polyphenols as anti-cancer agents. Biofactors 13: 81-85, 2000.
18. Hiura A, Tsutsumi M and Satake K: Inhibitory effect of green tea extract on the process of pancreatic carcinogenesis induced by N-nitrosobis-(2- oxypropyl)amine (BOP) and on tumor promotion after transplantation of N-nitrosobis-(2-hydroxypropyl) amine (BHP)-induced pancreatic cancer in Syrian hamsters. Pancreas 15: 272-277, 1997.
19. Ji BT, Chow WH, Hsing AW, McLaughlin JK, Dai Q, Gao YT, Blot WJ and Fraumeni JF Jr: Green tea consumption and the risk of pancreatic and colorectal cancers. Int J Cancer 70: 255-258, 1997.
20. Wang YC and Bachrach U: The specific anti-cancer activity of green tea (-)-epigallocatechin-3-gallate (EGCG). Amino Acids 22: 131-143, 2002.
21. Wu AH, Yu MC, Tseng CC, Hankin J and Pike MC: Green tea and risk of breast cancer in Asian Americans. Int J Cancer 106: 574-579, 2003.
22. Chung SY, Maliakal P and Meng X: Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 42: 25-54, 2002.
23. Yeh CW, Chen WJ, Chiang CT, Lin-Shiau SY and Lin JK: Suppression of fatty acid synthase in MCF-7 breast cancer cells by tea and tea polyphenols: a possible mechanism for their hypolipidemic effects. Pharmacogenomics J 3: 267-276, 2002.
24. Masuda M, Suzui M, Lim JT, Deguchi A, Soh JW and Weinstein IB: Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. J Exp Ther Oncol 2: 350-359, 2002.
25. Yamamoto T, Hsu S, Lewis J, Wataha J, Dickinson D, Singh B, Bollag WB, Lockwood P, Ueta E, Osaki T and Schuster G: Green tea polyphenol causes differential oxidative environments in tumor versus normal epithelial cells. J Pharmacol Exp Ther 307: 230-236, 2003.
26. Chung JH, Han JH, Hwang EJ, Seo JY, Cho KH, Kim KH, Youn JI and Eun HC: Dual mechanisms of green tea extract (EGCG)-induced cell survival in human epidermal keratinocytes. FASEB J 17: 1913-1915, 2003.
27. Chiou SK, Jones MK and Tarnawski AS: Survivin an antiapoptosis protein: its biological roles and implications for cancer and beyond. Med Sci Monit 9: PI25-PI29, 2003.
28. Ambrosini G, Adida C and Alteieri DC: A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921, 1997.
29. Mahotka C, Wenzel M, Springer E, Gabbert HE and Gerharz CD: Survivin-ΔEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 59: 6097-6102, 1999. (Pubitemid 30035627)
30. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T and Reed JC: IAP-family protein survivin inhibits caspase activity and apoptosis induced by FAS (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58: 5315-5320, 1998. (Pubitemid 28551107)
31. Suzuki A, Ito T, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y, Akahane K, Nakano T, Miura M and Shiraki K: Survivin initiates procaspase 3/p21 complex formation as a result of interaction with cdk4 to resist Fas-mediated cell death. Oncogene 19: 1346-1353, 2000. (Pubitemid 30160627)
32. Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, Pilotti S, Zunino F and Daidone MG: Expression of the antiapoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 59: 1406-1412, 2002.
33. Vergote D, Cren-Olive C, Chopin V, Toilion RA, Rolando C, Hondermarck H and Bourhis XL: Epigallocatechin (EGC) of green tea induces apoptosis of human breast cancer cells but not of their normal counterparts. Breast Cancer Res Treat 76: 195-201, 2002. (Pubitemid 35335209)
34. Kennedy SM, O'Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M, Linehan R and Clynes M: Prognostic importance of survivin in breast cancer. Br J Cancer 88: 1077-1083, 2003. (Pubitemid 36560779)
35. Singh M, Bleile MJ, Shroyer AL, Heinz D, Jarboe EA and Shroyer KR: Analysis of survivin expression in a spectrum of benign to malignant lesions of the breast. Appl Immunohistochem Mol Morphol 12: 296-304, 2004. (Pubitemid 39602068)
36. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M and Tanigawa N: Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 4: 127-134, 2000. (Pubitemid 30064984)
37. Chan HY, Wang H, Tsang DS, Chen ZY and Leung LK: Screening of chemopreventive tea polyphenols against PAH genotoxicity in breast cancer cells by a XRE-luciferase reporter construct. Nutr Cancer 46: 93-100, 2003.
38. Dohi T, Beltrami E, Wall NR, Plescia J and Altieri DC: Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 114: 1117-1127, 2004.
39. Burow ME, Weldon CB, Tang Y, Navar GL, Krajewski S, Reed JC, Hammond TG, Clejan S and Beckman BS: Differences in susceptibility to tumor necrosis factor alpha-induced apoptosis among MCF-7 breast cancer cell variants. Cancer Res 58: 4940-4946, 1998.
40. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB and Liu S: Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21: 2613-2622, 2002.
41. Wen SF, Xie L, McDonald M, Di Giacomo R, Chang A, Gurnani M, Shi B, Liu S, Indelicato SR, Hutchins B and Nielsen LL: Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models. Cancer Gene Ther 7: 1469-1480, 2000.
42. Ikeguchi M and Kaibara N: Survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Br J Cancer 87: 883-887, 2002. (Pubitemid 35252964)
43. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG and Anderson KC: Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 21: 5673-5683, 2002.
44. Suganuma M, Okabe S, Sueoka N, Sueoka E, Matsuyama S, Imai K, Nakachi K and Fujiki H: Green tea and cancer chemoprevention. Mutat Res 428: 339-344, 1999.
45. Pianetti S, Guo S, Kavanagh KT and Sonenshein GE: Green tea polyphenol epigallocatechin 3 gallate inhibits Her-2/Neu signaling, proliferation, and transformed phenotype of breast cancer cells. Cancer Res 62: 652-655, 2002.
46. Liberto M and Cobrinik D: Growth factor-dependent induction of p21(CIP1) by the green tea polyphenol, epigallocatechin gallate. Cancer Lett 154: 151-161, 2000.
47. Lin JK, Liang YC and Lin-Shiau SY: Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade. Biochem Pharmacol 58: 911-915, 1999.
48. Yanaga H, Fujii T, Koga T, Araki R and Shirouzu K: Prevention of carcinogenesis of mouse mammary epithelial cells RIII/MG by epigallocatechin gallate. Int J Mol Med 10: 311-315, 2002.
49. McCarty MF: Polyphenol-mediated inhibition of AP-1 transactivating activity may slow cancer growth by impeding angiogenesis and tumor invasiveness. Med Hypotheses 50: 511-514, 1998.
50. Dong Z, Ma W, Huang C and Yang CS: Inhibition of tumor promoter-induced activator protein 1 activation and cell transformation by tea polyphenols, (-)-epigallocatechin gallate, and theaflavins. Cancer Res 57: 4414-4419, 1997.
51. Ahmad N, Feyes DK, Nieminen A-L, Agarwal R and Mukhtar H: Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst 89: 1881-1886, 1997.
52. Mukhtar H and Ahmad N: Mechanism of cancer chemopreventive activity of green tea. Proc Soc Exp Biol Med 220: 234-238, 1999.
53. Hideshima T, Nakamura N, Chauhan D and Anderson KC: Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 20: 5991-6000, 2001. (Pubitemid 32955041)
54. Yaffe MB, Rittinger K, Volinia S, Caron PR, Aitken A, Leffers H, Gamblin SJ, Smerdon SJ and Cantley LC: The structural basis for 14-3-3:phosphopeptide binding specificity. Cell 91: 961-971, 1997. (Pubitemid 28027829)
55. Burow ME, Weldon CB, Collins-Burow BM, Ramsey N, McKee A, Klippel A, McLachlan JA, Clejan S and Beckman BS: Cross-talk between phosphatidylinositol 3-kinase and sphingomyelinase pathways as a mechanism for cell survival/death decisions. J Biol Chem 31: 9628-9635, 2000. (Pubitemid 30185195)
56. Franke TF and Cantley LC: Apoptosis: a bad kinase makes good. Nature 390: 116-117, 1997.